Transgene Biotek Ltd — Results, 07-05-2025: Result

Transgene Biotek has announced a board meeting on which it approved the audited financial results for the quarter and half-year ended March 31, 2025. The company reported total income of Rs. 104.42 lakh for the year with expenses rising to Rs. 172.03 lakh, leading to a loss of Rs. 67.61 lakh. Finance costs increased significantly, impacting profitability. The management has raised adequate secured debt and cleared payment dues with BIRAC. Clinical trials on oral insulin are progressing well without side effects. The company is contesting a Rs. 203.02 Cr penalty imposed by the Enforcement Directorate related to GDR regulations; the hearing is adjourned. The subsidiary Transgene Biotek HK Ltd remains non-operational with no material financial impact.